Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Stansfield SE, Heitner J, Mitchell KM, Doyle CM, Milwid RM, Moore M, Donnell DJ, Hanscom B, Xia Y, Maheu-Giroux M, Vijver DV, Wang H, Barnabas R, Boily MC, Dimitrov DT. Stansfield SE, et al. Among authors: hanscom b. J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26109. doi: 10.1002/jia2.26109. J Int AIDS Soc. 2023. PMID: 37439080 Free PMC article.
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
Donnell D, Gao F, Hughes JP, Hanscom B, Corey L, Cohen MS, Edupuganti S, Mgodi N, Rees H, Baeten JM, Gray G, Bekker LG, Hosseinipour M, Delany-Moretlwe S. Donnell D, et al. Among authors: hanscom b. J Int AIDS Soc. 2023 Jun;26(6):e26118. doi: 10.1002/jia2.26118. J Int AIDS Soc. 2023. PMID: 37363917 Free PMC article.
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, Chege W, Yacovone M, Hanscom B, Heptinstall J, Seaton KE, Zhang L, Miner MD, Eaton A, Weiner JA, Mayer K, Kalams S, Stephenson K, Julg B, Caskey M, Nussenzweig M, Gama L, Barouch DH, Ackerman ME, Tomaras GD, Huang Y, Montefiori D; HVTN 130/HPTN 089 Study Team. Sobieszczyk ME, et al. Among authors: hanscom b. Lancet HIV. 2023 Oct;10(10):e653-e662. doi: 10.1016/S2352-3018(23)00140-6. Lancet HIV. 2023. PMID: 37802566 Free PMC article. Clinical Trial.
Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
Marzinke MA, Han K, Hanscom B, Guo X, Piwowar-Manning E, Hendrix CW, Rose S, Spooner E, Mathew C, Innes S, Sekabira R, Mutambanengwe M, Rooney JF, Rinehart AR, Adeyeye A, Cohen MS, Hosseinipour M, Ford SL, Delany-Moretlwe S. Marzinke MA, et al. Among authors: hanscom b. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099424. doi: 10.1128/aac.00994-24. Epub 2024 Sep 23. Antimicrob Agents Chemother. 2024. PMID: 39311597 Clinical Trial.
Multiple Infection and Human Immunodeficiency Virus Superinfection Among Persons who Inject Drugs in Indonesia and Ukraine.
Palumbo PJ, Grant-McAuley W, Grabowski MK, Zhang Y, Richardson P, Piwowar-Manning E, Sharma D, Clarke W, Laeyendecker O, Rose S, Ha TV, Dumchev K, Djoerban Z, Redd A, Hanscom B, Hoffman I, Miller WC, Eshleman SH. Palumbo PJ, et al. Among authors: hanscom b. J Infect Dis. 2022 Dec 13;226(12):2181-2191. doi: 10.1093/infdis/jiac441. J Infect Dis. 2022. PMID: 36346452 Free PMC article.
Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial.
Dumchev K, Guo X, Ha TV, Djoerban Z, Zeziulin O, Go VF, Sarasvita R, Metzger DS, Latkin CA, Rose SM, Piwowar-Manning E, Richardson P, Hanscom B, Lancaster KE, Miller WC, Hoffman IF. Dumchev K, et al. Among authors: hanscom b. BMC Infect Dis. 2023 May 11;23(1):319. doi: 10.1186/s12879-023-08201-3. BMC Infect Dis. 2023. PMID: 37170118 Free PMC article. Clinical Trial.
Association between drug use and ART use among people living with HIV who inject drugs in Vietnam, Ukraine and Indonesia: results from HPTN 074.
Ha TV, Hoffman IF, Miller WC, Mollan KR, Lancaster KE, Richardson P, Zeziulin O, Djoerban Z, Sripaipan T, Chu VA, Guo X, Hanscom B, Go VF. Ha TV, et al. Among authors: hanscom b. J Subst Use. 2022;27(6):648-657. doi: 10.1080/14659891.2021.1989509. Epub 2022 Jan 10. J Subst Use. 2022. PMID: 36742268 Free PMC article.
Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084.
Delany-Moretlwe S, Hanscom B, Guo X, Nkabiito C, Mandima P, Nahirya PN, Mpendo J, Bhondai-Mhuri M, Mgodi N, Berhanu R, Farrior J, Piwowar-Manning E, Ford SL, Hendrix CW, Rinehart AR, Rooney JF, Adeyeye A, Landovitz RJ, Cohen MS, Hosseinipour MC, Marzinke MA; HPTN 084 Study Team. Delany-Moretlwe S, et al. Among authors: hanscom b. J Int AIDS Soc. 2025 Jan;28(1):e26401. doi: 10.1002/jia2.26401. J Int AIDS Soc. 2025. PMID: 39748218 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Edupuganti S, et al. Among authors: hanscom b. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. Lancet HIV. 2025. PMID: 39667379 Clinical Trial.
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Clement ME, et al. Among authors: hanscom b. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Online ahead of print. Clin Infect Dis. 2024. PMID: 39579334
80 results